2nd Special Session
Government Affairs & Regulatory Compliance Analysis
HB7 establishes a strict civil liability regime for the manufacture, transport, and provision of abortion-inducing drugs into Texas, enforced exclusively through private "qui tam" lawsuits with a statutory minimum penalty of $100,000 per violation. Logistics providers, common carriers, and employers with self-funded health plans face immediate exposure unless they adopt specific exclusionary policies and amend vendor contracts before September 1, 2025.
Rep. Jeff Leach·House Bill·2nd Special Session
This legislation has regulatory implications for the following Texas businesses and organizations:
Significant regulatory changes (effective 2025-09-01). Review with your legal and compliance teams to understand implications.
Affected business types:
highSignificant operational investment may be required.
JD Key Consulting provides government affairs and regulatory strategy services. We help businesses navigate Texas agencies, understand legislative impacts, and advocate for their interests.
JD Key Consulting provides strategic guidance on Texas regulatory compliance and legislative impact for your business.
Key implementation requirements and action items for compliance with this legislation
JD Key Consulting specializes in Texas regulatory compliance strategy. Work directly with James Dickey—former Chairman of the Republican Party of Texas—to understand this bill's impact on your operations and develop an actionable compliance plan.
Schedule a ConsultationInformation presented is for general knowledge only and is provided without warranty, express or implied. Consult qualified government affairs professionals and legal counsel before making compliance decisions.
This bill's path through the Texas Legislature
Showing first 50k characters.
View bill text in multiple formats on Texas Legislature websiteExplore more bills from this author and on related topics
Common questions about HB7
HB7 establishes a strict civil liability regime for the manufacture, transport, and provision of abortion-inducing drugs into Texas, enforced exclusively through private "qui tam" lawsuits with a statutory minimum penalty of $100,000 per violation. Logistics providers, common carriers, and employers with self-funded health plans face immediate exposure unless they adopt specific exclusionary policies and amend vendor contracts before September 1, 2025.
HB7 was authored by Texas Representative Jeff Leach during the 2nd Special Session.
HB7 was signed into law by Governor Greg Abbott on September 17, 2025.
The regulatory priority for HB7 is rated as "critical". Businesses and organizations should review the legislation to understand potential impacts.
The cost impact of HB7 is estimated as "high". This may vary based on industry and implementation requirements.
HB7 addresses topics including abortion, civil remedies & liabilities, courts, courts--general and woman & child protection act.
Key dates for HB7: Effective date is 2025-09-01. Consult with legal counsel regarding applicability.
HB7 establishes the following penalties: civil penalty of Minimum $100,000 per violation, plus injunctive relief, costs, and attorney's fees for Manufacturing, distributing, mailing, transporting, delivering, prescribing, or providing abortion-inducing drugs to/from any person or location in Texas.; civil penalty of Greater of: (2x damages + costs + fees) OR $100,000 for Bringing a 'clawback' action under the laws of another state against a person for complying with or enforcing this Texas Act.. Consult with legal counsel for specific applicability to your situation.
HB7 primarily affects healthcare providers and medical facilities. These businesses should review the legislation with their legal and compliance teams to understand potential impacts.
JD Key Consulting is an Austin, Texas-based government affairs firm led by James Dickey, former Chairman of the Republican Party of Texas. We specialize in Texas regulatory compliance and legislative strategy for data centers, energy, banking, and manufacturing.
